NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics

NCT07602881

Not Yet RecruitingN/A

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions: Severe Eosinophilic ACOS (Asthma-COPD Overlap)

Countries: China

Firstly, to screen blood exosomal multi-omics (transcriptomics, proteomics, metabolomics) and lung radiomics (HRCT, Xe129MRI) biomarkers that can predict efficacy and prognosis in severe eosinophilic ACOS (asthma-COPD overlap) patients treated with different biologics (benralizumab, mepolizumab, dupilumab). Then, to prospectively follow patients for 48 weeks after biologic initiation and collect clinical data, blood samples, and imaging features. Finally, to build a multi-dimensional predictive model for efficacy and prognosis of severe eosinophilic ACOS.

Eligibility overview

Sex: ALL

Age: 14 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥ 14 years
* Clinician decision to start biologic (benralizumab, mepolizumab, or dupilumab) for severe eosinophilic ACOS
* Blood eosinophils ≥150/μL within 3 months prior to informed consent, or ≥300/μL within 1 year prior
* Signed written informed consent

Exclusion Criteria:

* Currently participating in any other interventional clinical trial
* Known allergy or hypersensitivity to any component of the study drugs
* Any type of malignancy
* Prior or current biologic treatment for ACOS

Locations (1)

Wuhan, Hubei, China